Pharmacoeconomic issues in the treatment of depression

Stephen R Saklad

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The advent of newer, more expensive antidepressant agents in the past decade has focused renewed attention on major depressive disorder. The higher costs associated with purchasing the drugs makes their use appear to increase the cost of treating depression. Pharmacoeconomic methods are means of measuring the related advantages and costs, and provide guidance in drug selection. When such measures have been applied, the initial impression of increased costs for treating depressed persons with these agents is not supported. Pharmacoeconomic studies show that the newer antidepressants have clinically significant advantages that translate into lower total health system costs for treating major depressive disorder.

Original languageEnglish (US)
JournalPharmacotherapy
Volume15
Issue number6 II
StatePublished - 1995

Fingerprint

Pharmaceutical Economics
Depression
Costs and Cost Analysis
Major Depressive Disorder
Antidepressive Agents
Pharmaceutical Preparations
Health Care Costs

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacoeconomic issues in the treatment of depression. / Saklad, Stephen R.

In: Pharmacotherapy, Vol. 15, No. 6 II, 1995.

Research output: Contribution to journalArticle

Saklad, Stephen R. / Pharmacoeconomic issues in the treatment of depression. In: Pharmacotherapy. 1995 ; Vol. 15, No. 6 II.
@article{26d190c0bbde4e15b249685b95b462c9,
title = "Pharmacoeconomic issues in the treatment of depression",
abstract = "The advent of newer, more expensive antidepressant agents in the past decade has focused renewed attention on major depressive disorder. The higher costs associated with purchasing the drugs makes their use appear to increase the cost of treating depression. Pharmacoeconomic methods are means of measuring the related advantages and costs, and provide guidance in drug selection. When such measures have been applied, the initial impression of increased costs for treating depressed persons with these agents is not supported. Pharmacoeconomic studies show that the newer antidepressants have clinically significant advantages that translate into lower total health system costs for treating major depressive disorder.",
author = "Saklad, {Stephen R}",
year = "1995",
language = "English (US)",
volume = "15",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "6 II",

}

TY - JOUR

T1 - Pharmacoeconomic issues in the treatment of depression

AU - Saklad, Stephen R

PY - 1995

Y1 - 1995

N2 - The advent of newer, more expensive antidepressant agents in the past decade has focused renewed attention on major depressive disorder. The higher costs associated with purchasing the drugs makes their use appear to increase the cost of treating depression. Pharmacoeconomic methods are means of measuring the related advantages and costs, and provide guidance in drug selection. When such measures have been applied, the initial impression of increased costs for treating depressed persons with these agents is not supported. Pharmacoeconomic studies show that the newer antidepressants have clinically significant advantages that translate into lower total health system costs for treating major depressive disorder.

AB - The advent of newer, more expensive antidepressant agents in the past decade has focused renewed attention on major depressive disorder. The higher costs associated with purchasing the drugs makes their use appear to increase the cost of treating depression. Pharmacoeconomic methods are means of measuring the related advantages and costs, and provide guidance in drug selection. When such measures have been applied, the initial impression of increased costs for treating depressed persons with these agents is not supported. Pharmacoeconomic studies show that the newer antidepressants have clinically significant advantages that translate into lower total health system costs for treating major depressive disorder.

UR - http://www.scopus.com/inward/record.url?scp=0028882493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028882493&partnerID=8YFLogxK

M3 - Article

C2 - 8587854

AN - SCOPUS:0028882493

VL - 15

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 6 II

ER -